Clinical Trial Update: Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia (wAIHA) was terminated; results detailing safety, pharmacokin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 2 | Status: TERMINATED | Results posted: 2024-08-27